| Literature DB >> 27092515 |
Grigoris D Amoutzias1, Anargyros Chaliotis2, Dimitris Mossialos3.
Abstract
Considering that 70% of our planet's surface is covered by oceans, it is likely that undiscovered biodiversity is still enormous. A large portion of marine biodiversity consists of microbiomes. They are very attractive targets of bioprospecting because they are able to produce a vast repertoire of secondary metabolites in order to adapt in diverse environments. In many cases secondary metabolites of pharmaceutical and biotechnological interest such as nonribosomal peptides (NRPs) and polyketides (PKs) are synthesized by multimodular enzymes named nonribosomal peptide synthetases (NRPSes) and type-I polyketide synthases (PKSes-I), respectively. Novel findings regarding the mechanisms underlying NRPS and PKS evolution demonstrate how microorganisms could leverage their metabolic potential. Moreover, these findings could facilitate synthetic biology approaches leading to novel bioactive compounds. Ongoing advances in bioinformatics and next-generation sequencing (NGS) technologies are driving the discovery of NRPs and PKs derived from marine microbiomes mainly through two strategies: genome-mining and metagenomics. Microbial genomes are now sequenced at an unprecedented rate and this vast quantity of biological information can be analyzed through genome mining in order to identify gene clusters encoding NRPSes and PKSes of interest. On the other hand, metagenomics is a fast-growing research field which directly studies microbial genomes and their products present in marine environments using culture-independent approaches. The aim of this review is to examine recent developments regarding discovery strategies of bioactive compounds synthesized by NRPS and type-I PKS derived from marine microbiomes and to highlight the vast diversity of NRPSes and PKSes present in marine environments by giving examples of recently discovered bioactive compounds.Entities:
Keywords: bioactive compounds; bioprospecting; evolution; genome mining; marine microbiomes; metagenomics; nonribosomal peptide synthetase; polyketide synthase
Mesh:
Substances:
Year: 2016 PMID: 27092515 PMCID: PMC4849084 DOI: 10.3390/md14040080
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Module organization of nonribosomal peptide synthetases and type-I polyketide synthases. (A) A typical module of NRPSes consists of three main domains: C, A and T. The condensation domain (C) is responsible for the formation of the C–N bond between the elongated chain and the activated amino acid. The adenylation (A) domain activates its related amino acid and catalyzes the transfer of the activated substrate to thiolation (peptidyl-carrier) (T) domain of the same module. The epimerization domain (E) is an auxiliary domain that changes an l-amino acid into a d-amino acid. Each module is responsible for the incorporation of one monomer in the elongated oligopeptide. TE domain releases the final peptide product from the enzyme through cyclization or hydrolysis; (B) A prototypical module of type-I PKSes consists of the following domains: KS, AT and T. The AT domains are responsible for the incorporation of malonyl or methylmalonyl-CoA monomers, while the KS domains form a C–C bond. Acyl carrier (T) domains are equivalent to PCP (T) domains of NRPS. Each module is responsible for the incorporation of one monomer in the elongated polyketide. TE domain releases the final polyketide product from the assembly line. Type-I PKS proteins may interact in a head to tail fashion, thus forming a megasynthase. AT-less PKSes-I are characterized by the absence of integrated AT domains within each extension module. Instead, a free-standing AT domain named discreet AT acts in-trans through binding to the remnant AT domain within the module.
NRPS and PKS content in 46 marine prokaryotic genomes after applying a set of filters. Of note, the number of C and KS domains corresponds only to filtered proteins.
| Species | C and KS Domains | C Domains | Total NRPS and PKS Proteins | NRPS (or NRPS/PKS Hybrid) Proteins |
|---|---|---|---|---|
| 10 | 10 | 6 | 6 | |
| 16 | 16 | 10 | 10 | |
| 16 | 16 | 10 | 10 | |
| 16 | 16 | 10 | 10 | |
| 16 | 16 | 10 | 10 | |
| 16 | 16 | 10 | 10 | |
| 41 | 24 | 15 | 9 | |
| 4 | 4 | 2 | 2 | |
| 14 | 14 | 4 | 4 | |
| 3 | 3 | 1 | 1 | |
| 18 | 18 | 8 | 8 | |
| 73 | 64 | 24 | 21 | |
| 3 | 3 | 1 | 1 | |
| 61 | 52 | 29 | 25 | |
| 9 | 7 | 7 | 7 | |
| 18 | 17 | 10 | 10 | |
| 3 | 1 | 2 | 1 | |
| 14 | 14 | 10 | 10 | |
| 16 | 16 | 12 | 12 | |
| 1 | 1 | 1 | 1 | |
| 1 | 1 | 1 | 1 | |
| 1 | 1 | 1 | 1 | |
| 9 | 8 | 4 | 4 | |
| 2 | 0 | 1 | 0 | |
| 2 | 0 | 1 | 0 | |
| 1 | 1 | 1 | 1 | |
| 9 | 7 | 5 | 5 | |
| 42 | 25 | 21 | 16 | |
| 28 | 16 | 19 | 15 | |
| 2 | 2 | 1 | 1 | |
| 3 | 3 | 1 | 1 | |
| 3 | 3 | 2 | 2 | |
| 9 | 9 | 7 | 7 | |
| 5 | 5 | 2 | 2 | |
| 5 | 5 | 2 | 2 | |
| 5 | 5 | 2 | 2 | |
| 5 | 5 | 2 | 2 | |
| 5 | 5 | 2 | 2 | |
| 5 | 5 | 2 | 2 | |
| 10 | 10 | 4 | 4 | |
| 5 | 5 | 3 | 3 | |
| 25 | 24 | 12 | 12 | |
| 1 | 1 | 1 | 1 | |
| 4 | 4 | 3 | 3 | |
| 4 | 4 | 3 | 3 | |
| 4 | 4 | 3 | 3 | |
| Total | 563 | 486 | 288 | 263 |
NRPs and PKs compounds derived from marine microbiomes discovered though genome mining and metagenomics.
| Compound | Enzyme | Discovering Approach | Microbial Source | Mode of Action | Reference |
|---|---|---|---|---|---|
| Haliamide | PKS-NRPS | Genome mining | Cytotoxic | [ | |
| Salinosporamide K | NRPS | Genome mining | Antitumor | [ | |
| Retimycin A | NRPS | Genome mining | Antitumor | [ | |
| Salinilactam A | PKS | Genome mining | Antibiotic | [ | |
| ET-743 | NRPS | Metagenomics | Antitumor | [ | |
| Pederin | PKS | Metagenomics | Antitumor | [ | |
| Bryostatin | PKS | Metagenomics | Antitumor | [ | |
| Apratoxin A | PKS-NRPS | Metagenomics | Antitumor | [ | |
| Onnamide | PKS-NRPS | Metagenomics | Antitumor | [ |
Figure 2General workflow in metagenomics. Sequenced-based and/or functional approaches are commonly adopted in order to discover new natural products, to study microbial communities or to sequence whole genomes of unculturable single cells.